Ovarian cancer is the fifth leading cause of cancer death in women worldwide. Most of these cancers are manifested in the form of an ovarian cyst. Practitioners are faced with two main difficulties. The first is to establish an early diagnosis. The second is to differentiate a benign tumor, a malignant tumor. To date, there is only one biological tumor marker routinely performed before an ovarian cyst, the CA-125 (cancer antigen 125). Unfortunately, many studies have been performed and show a sensitivity and specificity unsatisfactory in view of the severity of the disease. The principal investigator therefore propose to evaluate a new tumor marker, as well as its use in algorithms to help differentiate benign from malignant tumors, and allow earlier diagnosis in cases of ovarian cancer.
Study Type
OBSERVATIONAL
Enrollment
221
Centre Hospitalier de Cholet
Cholet, France
CHD Vendée
La Roche-sur-Yon, France
CHU de Nantes
Nantes, France
CH de Saint Nazaire
Saint-Nazaire, France
Tumor Marker CA125
CA125 \< 35U/mL. Abnormal score if CA125 \> 35U/mL.
Time frame: Baseline
Tumor Marker HE4
HE4 \< 70 pmol/L for premenopausal women or \< 140 pmol/L for postmenopausal women Abnormal score if HE4 \> 70 pmol/L for premenopausal women or \> 140 pmol/L for postmenopausal women
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.